medicina57巻9号

2020年08月発行

特集 患者満足度の高い便秘診療 なぜ便秘は生命予後が悪いか〜疫学とそのメカニズムに迫る

腎疾患における便秘治療の重要性

著者： 菊地晃一¹² 阿部高明¹³⁴

所属機関： ¹東北大学病院腎・高血圧・内分泌科 ²東北大学東北メディカル・メガバンク機構 ³東北大学大学院医工学研究科分子病態医工学分野 ⁴東北大学大学院医学系研究科病態液性制御学分野

ページ範囲：P.1429 - P.1432

Point
◎慢性腎臓病と腸内環境が密接に関係する「腸腎連関」が明らかになっている．
◎便秘症は慢性腎臓病（CKD）の発症や進行と密接に関係している．
◎腸腎連関のキーワードの1つが尿毒素であり，腸内細菌叢由来の尿毒素の蓄積がさらに腎機能を悪化させる悪循環に陥る．
◎便秘による大腸内の内容物滞留時間の延長は腸内細菌由来尿毒素産生の亢進や吸収増加をもたらし，CKDの病態を悪化させうる．
◎適切な便通管理はCKDの治療選択肢の1つになりうる．

参考文献

1）Jha V, et al：Chronic kidney disease；Global dimension and perspectives. Lancet 382：260-272, 2013

2）Ramezani A, et al：Role of the gut microbiome in uremia；A potential therapeutic target. Am J Kidney Dis 67：483-498, 2016

3）Vaziri ND, et al：Chronic kidney disease alters intestinal microbial flora. Kidney Int 83：308-315, 2013

4）Nigam SK, et al：Uraemic symdrome of chronic kidney disease；Altered remotesensing and signaling. Nat Rev Nephrol 15：301-316, 2019

5）Fishbane S, et al：Iron toxicity；Relevance for dialysis patients. Nephrol Dial Transplant 29：255-259, 2014

6）Joo M, et al：Colonic mucosal necrosis following administration of calcium polystryrene sulfonate（Kalimate）in a uremic patient. J Korean Med Sci 24：1207-1211, 2009

7）Wu MJ, et al：Colonic transit time in long-term dialysis patients. Am J Kidney Dis 44：322-327, 2004

8）Sumida K, et al：Constipation and incident CKD. J Am Soc Nephrol 28：1248-1258, 2017

9）Mishima E, et al：Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int 92：634-645, 2017

10）Kikuchi K, et al：Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 10：1835, 2019

11）Wong J, et al：Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 9：230-237, 2014

12）Niwa T, et al：Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 72：1-11, 2010

13）Sato E, et al：Impact of the oral adsorbent AST-120 on organ-specific accumulation of uremic toxins；LC-MS/MS and MS imaging techniques. Toxins（Basel）10：19, 2017

14）Sato E, et al：Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep 6：36618, 2016

15）Koeth RA, et al：Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19：576-585, 2013

16）Zhu W, et al：Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165：111-124, 2016

17）Xu KY, et al：Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep 7：1445, 2017

18）Roager HM, et al：Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat Microbiol 1：16093, 2016

19）Mishima E, et al：Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26：1787-1794, 2015

20）Nanto-Hara F, et al：The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant 35：250-264, 2020

21）Sueyoshi M, et al：Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol 23：908-919, 2019